Why does compounded semaglutide exist, and what does it cost?
Branded semaglutide (Ozempic for diabetes management, Wegovy for weight management) can cost $900–$1,400 per month out of pocket without insurance coverage. For most patients, that price is prohibitive without insurance — and coverage for weight management medications remains inconsistent.
Compounded semaglutide provides access to the same active molecule at substantially lower cost because licensed 503A compounding pharmacies prepare it to order without the commercialization overhead embedded in branded drug pricing. The active pharmaceutical ingredient is the same; the regulatory pathway, manufacturing scale, and pricing structure differ significantly.
Typical compounded semaglutide cost ranges from approximately $150 to $350 per month, depending on dose and program structure. The lower end of that range usually reflects starter doses (0.25–0.5 mg/week); higher maintenance doses cost more because larger volumes of API are used per dose.
What drives the price difference between compounded semaglutide providers?
The wide range in compounded semaglutide pricing — from suspiciously cheap to significantly more expensive — reflects real differences in several components:
Pharmacy quality and sourcing
A licensed 503A compounding pharmacy in the USA uses USP-grade active pharmaceutical ingredients (API), runs sterility testing on injectable products, maintains certificates of analysis (COAs) for every batch, and operates under state pharmacy board and FDA oversight. This costs more than sourcing cheaper, less-verified API — often from international suppliers with no US regulatory accountability.
Extremely low compounded semaglutide pricing (under $100/month at full doses) is a signal worth scrutinizing. The math on pharmacy overhead, quality testing, and a real clinician review does not support those prices without cutting somewhere — and in injectables, cutting on quality carries real risk.
PepScribe works only with licensed 503A compounding pharmacies in the USA. No hidden overseas supply chain.
Clinician oversight
A legitimate compounded semaglutide protocol requires a licensed clinician to review your medical history before prescribing. That review screens for contraindications (history of pancreatitis, MEN2, medullary thyroid carcinoma history, medication interactions), determines the appropriate starting dose, and documents the prescription to the compounding pharmacy.
Programs that appear to provide prescriptions without real clinical review (rubber-stamp questionnaires, no follow-up) may be less expensive but represent a lower standard of care. The prescriber is responsible for that decision, not just the patient.
Included supplies and follow-up
A complete monthly cost may include syringes, needles, alcohol swabs, and reconstitution supplies — or these may be separate. Ongoing check-in visits, dose adjustments, and messaging access with your care team also vary by program. Compare what is included when evaluating total cost.
The real variable behind compounded semaglutide’s price isn’t the molecule — it’s the pharmacy quality and clinician oversight you’re paying for.
Compounded vs. branded semaglutide: what is the regulatory distinction?
This is a critical point that should be clearly understood before starting any protocol:
- Branded semaglutide (Ozempic, Wegovy) is an FDA-approved drug manufactured by Novo Nordisk to exacting Good Manufacturing Practice standards with full FDA oversight of every production batch.
- Compounded semaglutideis not FDA-approved. It is prepared by licensed pharmacies under state pharmacy board and FDA oversight, but the compounded product itself does not carry an FDA approval. Quality depends on the individual pharmacy’s standards and processes.
- Never claim equivalenceto the branded drug. Never say “same as Ozempic” or “same as Wegovy.” The active molecule is the same; the regulatory status is not.
How does the shortage affect availability?
Compounded semaglutide became widely available when the FDA designated branded semaglutide as being in shortage — a designation that allows licensed compounding pharmacies to prepare and dispense the compound under specific conditions. The FDA reviews shortage status periodically.
The regulatory landscape for compounded GLP-1 medications is actively evolving. Your clinician and pharmacy will be current on what is permitted. This is one of the reasons ongoing clinician contact matters: if the regulatory status shifts, you need a prescriber who can adjust your protocol accordingly.
What does a full protocol cost?
Beyond the monthly medication cost, a complete compounded semaglutide protocol involves:
- Initial consultation: A clinician review before prescribing. This is a one-time or periodic cost depending on the program model.
- Medication (monthly): $150–$350 depending on dose and provider.
- Supplies: Syringes, needles, alcohol swabs — often included in pharmacy kits but sometimes separate.
- Follow-up check-ins: Periodic clinician review for dose adjustments and monitoring. Standard of care, not optional.
The total monthly cost for a clinician-supervised compounded semaglutide program from a quality provider typically falls in the range of $200–$400/month all-in — still substantially less than the out-of-pocket cost of the branded drug.
| Cost component | Typical range | Notes |
|---|---|---|
| Initial consultation | $0–$75 one-time | Some programs bundle it into month 1 |
| Medication (starter dose 0.25 mg) | $150–$200/month | Lower API volume; lower pharmacy cost |
| Medication (maintenance dose) | $250–$350/month | Higher dose requires more API per vial |
| Supplies (syringes, swabs) | Included – $20/month | Often bundled in pharmacy kit |
| Follow-up check-ins | Included or $25–$50 | Varies by program model |
| Branded Ozempic/Wegovy (out-of-pocket) | $900–$1,400/month | Without insurance coverage |
Frequently asked questions
How much does compounded semaglutide cost per month?
Compounded semaglutide cost typically ranges from roughly $150 to $350 per month depending on the dose, the pharmacy, and what is included in the program (clinician visits, supplies, check-ins). Lower-dose starter months cost less; maintenance doses at higher concentrations cost more. Pricing that seems unusually low often reflects quality trade-offs in the pharmacy sourcing.
Why is compounded semaglutide cheaper than the branded drug?
Branded semaglutide (Ozempic, Wegovy) carries extensive FDA-approval costs, manufacturing overhead, and distributor margins. Compounded semaglutide is prepared by licensed 503A pharmacies to order, without the same commercialization overhead. The active molecule is the same; the regulatory status and pricing structure differ significantly.
Is compounded semaglutide the same as Ozempic or Wegovy?
The active molecule is the same — semaglutide. Compounded semaglutide is not FDA-approved and is not manufactured by Novo Nordisk. It is prepared by a licensed compounding pharmacy per a clinician's prescription. The quality depends entirely on the pharmacy's standards. Never claim equivalence to a branded product or imply FDA approval of a compounded formulation.
Is compounded semaglutide covered by insurance?
Compounded medications are generally not covered by insurance. The cost comparison that matters for most patients is compounded semaglutide vs. paying out-of-pocket for the branded drug (often $900–$1,400/month without coverage). At $150–$350/month, the compound is substantially lower cost for the same active molecule under a clinician's supervision.
What should I look for to evaluate compounded semaglutide cost vs. quality?
The most important factor is whether the pharmacy is a licensed 503A compounding pharmacy in the USA. Certificates of analysis (COAs), USP-grade API sourcing, and sterility testing documentation are additional markers of quality. Be skeptical of pricing that undercuts the market significantly — extremely low cost often reflects lower quality controls or gray-market API sourcing.
Does the semaglutide shortage affect compounded semaglutide availability?
FDA policy on compounded semaglutide availability is tied to the official drug shortage status. When branded semaglutide is on the FDA shortage list, compounding is permitted under specific conditions. The shortage status is reviewed periodically. Your clinician and pharmacy will be aware of the current regulatory posture.